Search Results
You are looking at 1 - 2 of 2 items for
- Author: Namrata Setia x
- Refine by access: All content x
Search for other papers by Rushabh Gujarathi in
Google Scholar
PubMed
Search for other papers by Sara Abou Azar in
Google Scholar
PubMed
Search for other papers by Joseph Tobias in
Google Scholar
PubMed
Search for other papers by Blase N Polite in
Google Scholar
PubMed
Search for other papers by Namrata Setia in
Google Scholar
PubMed
Search for other papers by Nicholas Feinberg in
Google Scholar
PubMed
Search for other papers by Daniel E Appelbaum in
Google Scholar
PubMed
Search for other papers by Xavier M Keutgen in
Google Scholar
PubMed
Search for other papers by Chih-Yi Liao in
Google Scholar
PubMed
Pre-clinical data suggest that mutations in the MEN1, DAXX, and/or ATRX genes may potentially increase radiation efficacy in cancer cells. Herein, we explore the association between response to peptide receptor radionuclide therapy (PRRT) and those mutations in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We analyzed tissue-based next generation sequencing (NGS) assay results and clinicopathologic data from 28 patients with GEP-NETs treated with PRRT. Findings were correlated with progression-free survival (PFS) and objective response rate (ORR). Patients with mutations in MEN1, DAXX, and/or ATRX (n = 13) had a longer median PFS (26.47 vs 12.13 months; P = 0.014) than wild-type (n = 15) patients when adjusted for surgery prior to PRRT, tumor grade, and presence of TP53 mutation. Alterations in MEN1 along with a concurrent mutation in either DAXX or ATRX (n = 6) trended toward longer PFS compared to patients without concurrent mutations (31.53 vs 17.97 months; P = 0.09). ORR was higher in patients with a mutation in MEN1, DAXX, or ATRX (41.67% vs 15.38%). In pancreatic NET patients, these target mutations also showed a longer PFS (28.43 vs 9.83 months; P = 0.04). TP53 alterations showed a shorter PFS than wild-type cases (11.17 vs 20.47 months; P = 0.009). Mutations in MEN1/DAXX/ATRX are associated with improved PFS in patients with GEP-NETs receiving PRRT and might be used as a biomarker for treatment response.
Search for other papers by Olga Lakiza in
Google Scholar
PubMed
Search for other papers by Julian Lutze in
Google Scholar
PubMed
Search for other papers by Alyx Vogle in
Google Scholar
PubMed
Search for other papers by Jelani Williams in
Google Scholar
PubMed
Search for other papers by Abde Abukdheir in
Google Scholar
PubMed
Search for other papers by Paul Miller in
Google Scholar
PubMed
Search for other papers by Chih-Yi ‘Andy’ Liao in
Google Scholar
PubMed
Search for other papers by Sean P Pitroda in
Google Scholar
PubMed
Search for other papers by Carlos Martinez in
Google Scholar
PubMed
Search for other papers by Andrea Olivas in
Google Scholar
PubMed
Search for other papers by Namrata Setia in
Google Scholar
PubMed
Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, Illinois, USA
Search for other papers by Stephen J Kron in
Google Scholar
PubMed
Ludwig Center for Metastasis Research, University of Chicago, Chicago, Illinois, USA
Search for other papers by Ralph R Weichselbaum in
Google Scholar
PubMed
Search for other papers by Xavier M Keutgen in
Google Scholar
PubMed
Somatic MEN1 mutations occur in up to 50% of pancreatic neuroendocrine tumors (PanNETs). Clinical studies have shown that radiation therapy (IR) is effective in a subset of PanNETs, but it remains unclear why some patients respond better to IR than others. Herein, we study whether MEN1 loss of function increases radiosensitivity of PanNETs and determine its effect on DNA double-strand break (DSB) repair. After creating a MEN1 knockout PanNET cell line, we confirmed reduced DSB repair capacity in MEN1-deficient cells and linked these findings to a defect in homologous recombination, as well as reduced BRCA2 expression levels. Consistent with this model, we found that MEN1 mutant cells displayed increased sensitivity to the highly trapping poly (ADP-ribose) polymerase (PARP) 1 inhibitor talazoparib in vitro. Our results suggest that combining IR with PARP inhibition may be beneficial in patients with PanNETs and MEN1 loss of function.
